304
Participants
Start Date
June 4, 2019
Primary Completion Date
February 4, 2022
Study Completion Date
September 22, 2022
Secukinumab/Adalimumab-Biosimilar
Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab biosimilar 40 mg, s.c.
Standard-of-care
Treatment according to local practice standards by the rheumatologist following latest treatment recommendations with NSAIDs as the first-choice drug treatment and DMARDs for patients with active disease despite the use (or intolerance/contraindication) of NSAIDs.
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Potsdam
Novartis Investigative Site, Bad Doberan
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Rendsburg
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Hildesheim
Novartis Investigative Site, Bad Pyrmont
Novartis Investigative Site, Montpellier
Novartis Investigative Site, Ehringshausen
Novartis Investigative Site, Chambray-lès-Tours
Novartis Investigative Site, Grenoble
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Gommern
Novartis Investigative Site, Ratingen
Novartis Investigative Site, Nantes
Novartis Investigative Site, Herne
Novartis Investigative Site, Orléans
Novartis Investigative Site, Cologne
Novartis Investigative Site, Bonn
Novartis Investigative Site, Trier
Novartis Investigative Site, Vandœuvre-lès-Nancy
Novartis Investigative Site, Mainz
Novartis Investigative Site, Caluire-et-Cuire
Novartis Investigative Site, Le Mans
Novartis Investigative Site, Paris
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, München
Novartis Investigative Site, München
Novartis Investigative Site, La Roche-sur-Yon
Novartis Investigative Site, Limoges
Novartis Investigative Site, Ulm
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Nice
Novartis Investigative Site, Chemnitz
Novartis Investigative Site, Cottbus
Novartis Investigative Site, Dresden
Novartis Investigative Site, Dresden
Novartis Investigative Site, Freiberg
Novartis Investigative Site, Gera
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY